Cybersecurity & Cloud Systems

Cybersecurity Documentation for Premarket Approval (PMA) Submissions

February 9, 2024
|
By Dr. Ebot Eyong

Cybersecurity documentation is vital for PMA submissions to the FDA, ensuring device safety and effectiveness. This article outlines cybersecurity risk assessment, security controls, SBOM, vulnerability disclosure, incident response planning, labeling, monitoring, and documentation requirements.

Cybersecurity documentation is vital for PMA submissions to the FDA, ensuring device safety and effectiveness.

FDA Guidance on Cybersecurity Documentation

The FDA’s guidance document titled "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions" (June 2025) provides recommendations for the industry on cybersecurity related to device design, labeling, and documentation for premarket submissions.

Key Components Outlined in FDA Guidance

  • Cybersecurity Risk Assessment: This involves identifying and assessing the cybersecurity risks associated with the medical device, including potential threats, vulnerabilities, and harm.
  • Security Controls: This involves implementing measures, including encryption, access controls, and incident response plans, to mitigate the identified risks.
  • Software Bill of Materials (SBOM): A comprehensive list detailing all software components utilized in the device, along with their versions and any known vulnerabilities.
  • Vulnerability Disclosure Policy: A defined process for reporting and addressing security vulnerabilities in the device.
  • Incident Response Plan: Procedures for responding to security incidents, including notification steps and mitigation strategies.

Premarket Submission Requirements

  • Cybersecurity Risk Management Report: This includes a detailed report that describes the cybersecurity risk assessment and the strategies for mitigating those risks.
  • Cybersecurity Documentation: Submission of comprehensive documentation detailing cybersecurity controls, which includes design specifications, testing protocols, and validation results.
  • Labeling and Instructions: Provide clear labels and instructions to inform users about cybersecurity risks and the strategies implemented for mitigation.

Key Components of Cybersecurity Documentation

  • System Security Plan: This document describes the purpose, scope, management, and security controls of the medical device system to safeguard the device and data.
  • Cybersecurity Incident Response Plan: It details procedures for handling incidents, including defining incident types and reporting requirements.
  • Change and Configuration Management Plan: This plan explains how to manage device configuration updates, including the processes for requesting, tracking, and documenting changes to maintain system integrity.
  • Continuous Monitoring Plan: Regular monitoring includes conducting vulnerability scans, assessments, and penetration tests to identify and reduce security risks.
  • Security Assessment Report: This report provides an overview of the system's strengths, weaknesses, and recommended fixes.
  • Action Plan and Milestones: This section outlines specific steps and deadlines for addressing security issues and implementing the recommended actions.

For more information, visit https://eemedicals.com/

Explore More Publications

Continue exploring Dr. Ebot Eyong’s professional insights on healthcare regulation, FDA submissions, AI-enabled medical devices, quality systems, and global compliance strategy.

AI & Digital Health

Challenges in Medical Device AI Validation

June 18, 2026
|
Dr. Ebot Eyong

The most difficult aspect is ensuring that an AI system remains reliable after deployment as patient populations, clinical practices, and data characteristics evolve over time. This has led regulators to shift from a one-time validation model toward a lifecycle-based approach involving continuous monitoring and revalidation.

Read Article

EU Regulatory Strategy

EU Proposal to Revise MDR and IVDR: Implications for Innovation, Documentation, and Software Oversight

February 17, 2026
|
By Dr. Ebot Eyong

The European Commission has proposed a targeted revision of the Medical Device Regulation and In Vitro Diagnostic Regulation aimed at supporting innovation while reducing unnecessary administrative burden. This article explores the impact on technical documentation, manufacturers, implementation challenges, and software oversight.

Read Article

Real-World Evidence

Real-World Evidence (RWE) and Biocompatibility: Implications of ISO 10993-1:2025 for Medical Device Manufacturers

December 11, 2025
|
By Dr. Ebot Eyong

The revised ISO 10993-1 marks a significant shift in biocompatibility assessment by enabling risk-based justifications supported by real-world evidence. This article explores pre-market submissions, manufacturer implications, AI-enabled device challenges, and regulatory pitfalls.

Read Article

AI & Digital Health

FDA Expands Digital Health Exemptions: Implications for AI-Enabled Medical Devices

December 18, 2025
|
By Dr. Ebot Eyong

FDA’s revised digital health guidance expands exemptions for certain low-risk digital health products from active regulatory oversight. This article explains how wearables, wellness products, clinical decision support tools, and AI-enabled software may be affected by the updated risk-based approach.

Read Article